[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
|
[2] |
成晓芬, 闵淑慧, 郭芮绮, 等. 1990—2019年中国胃癌发病与死亡率年龄-时期-队列分析及2020—2030年变化趋势预测[J]. 中国肿瘤, 2023, 32(6): 454-461. DOI: 10.11735/j.issn.1004-0242.2023.06.A008.
|
[3] |
马甘青, 李路遥, 刘吉祥, 等. 进展期胃癌免疫治疗的研究进展[J/OL]. 中国普外基础与临床杂志.[2023-10-24][2023-11-15]. http://www.gensurg.cn/article/10.7507/1007-9424.202308008. DOI: 10.7507/1007-9424.202308008.
|
[4] |
Naimi A, Mohammed RN, Raji A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons[J]. Cell Commun Signal, 2022, 20(1): 44. DOI: 10.1186/s12964-022-00854-y.
pmid: 35392976
|
[5] |
徐泽宇, 汪海岩, 田园. 卡瑞利珠单抗联合白蛋白紫杉醇二线治疗晚期胃癌的疗效及安全性[J]. 现代肿瘤医学, 2023, 31(1): 130-134. DOI: 10.3969/j.issn.1672-4992.2023.01.024.
|
[6] |
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. DOI: 10.1016/S0140-6736(21)00797-2.
pmid: 34102137
|
[7] |
Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation have antiinflammatory therapies come of age?[J]. Nat Rev Clin Oncol, 2021, 18(5): 261-279. DOI: 10.1038/s41571-020-00459-9.
|
[8] |
Murakami Y, Saito H, Shimizu S, et al. Neutrophil-to-lymphocyte ratio as a prognostic indicator in patients with unresectable gastric cancer[J]. Anticancer Res, 2019, 39(5): 2583-2589. DOI: 10.21873/anticanres.13381.
pmid: 31092456
|
[9] |
陆通, 房钰, 刘浩楠, 等. 基于术前PIV、NLR和CEA水平对胃癌根治术后预后列线图预测模型的构建及评价[J]. 现代肿瘤医学, 2023, 31(10): 1869-1875. DOI: 10.3969/j.issn.1672-4992.2023.0.018.
|
[10] |
Lang D, Horner A, Brehm E, et al. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study[J]. Lung Cancer, 2019, 134: 59-65. DOI: 10.1016/j.lungcan.2019.05.033.
|
[11] |
Tang Y, Cui Y, Li LL, et al. Dynamics of early serum tumour markers and neutrophil-to-lymphocyte ratio predict response to PD-1/PD-L1 inhibitors in advanced non-small-cell lung cancer[J]. Cancer Manag Res, 2021, 13: 8241-8255. DOI: 10.2147/CMAR.S329963.
pmid: 34754244
|
[12] |
姜志超. 晚期胃癌一线免疫治疗的现状与进展[J]. 中国肿瘤临床, 2023, 50(4): 206-211. DOI: 10.12354/j.issn.1000-8179.2023.20221371.
|
[13] |
Chang X, Ge X, Zhang Y, et al. The current management and biomarkers of immunotherapy in advanced gastric cancer[J]. Medicine (Baltimore), 2022, 101(21): e29304. DOI: 10.1097/MD.0000000000029304.
|
[14] |
Chao J, Fuchs CS, Shitara K, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials[J]. JAMA Oncol, 2021, 7(6): 895-902. DOI: 10.1001/jamaoncol.2021.0275.
pmid: 33792646
|
[15] |
Liu X, Guo CY, Tou FF, et al. Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: a systematic review and meta-analysis[J]. Int J Cancer, 2020, 147(1): 116-127. DOI: 10.1002/ijc.32744.
pmid: 31633798
|
[16] |
McGrail DJ, Pilié PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types[J]. Ann Oncol, 2021, 32(5): 661-672. DOI: 10.1016/j.annonc.2021.02.006.
pmid: 33736924
|
[17] |
Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation— have anti-inflammatory therapies come of age?[J]. Nat Rev Clin Oncol, 2021, 18(5): 261-279. DOI: 10.1038/s41571-020-00459-9.
|
[18] |
杨宁, 张伟, 钱峰, 等. 外周血PLR和NLR与Ⅲ、Ⅳ期胃癌患者化疗后预后相关性[J]. 分子诊断与治疗杂志, 2023, 15(1): 52-55. DOI: 10.3969/j.issn.1674-6929.2023.01.014.
|
[19] |
范东, 葛萍萍, 吴琼, 等. 外周血NLR和PLR在胃癌中的研究进展[J]. 肿瘤学杂志, 2022, 28(4): 291-297. DOI: 10.11735/j.issn.1671-170X.2022.04.B007.
|
[20] |
Ota Y, Takahari D, Suzuki T, et al. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival[J]. Cancer Chemother Pharmacol, 2020, 85(2): 265-272. DOI: 10.1007/s00280-019-04023-w.
|
[21] |
Yamada T, Hayashi T, Inokuchi Y, et al. Impact of the neutrophil-to-lymphocyte ratio on the survival of patients with gastric cancer treated with nivolumab monotherapy[J]. Target Oncol, 2020, 15(3): 317-325. DOI: 10.1007/s11523-020-00716-y.
pmid: 32319020
|
[22] |
Gou M, Qu T, Wang Z, et al. Neutrophil-to-lymphocyte ratio(NLR)predicts PD-1 inhibitor survival in patients with metastatic gastric cancer[J]. J Immunol Res, 2021, 2021: 2549295. DOI: 10.1155/2021/2549295.
|
[23] |
Wan M, Ding Y, Mao C, et al. Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment[J]. Front Oncol, 2022, 12: 1029960. DOI: 10.3389/fonc.2022.1029960.
|
[24] |
Wang J, Qu J, Li Z, et al. Pretreatment platelet-to-lymphocyte ratio is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer[J]. J Clin Lab Anal, 2018, 32(1): e22185. DOI: 10.1002/jcla.22185.
|
[25] |
胡白娥, 王丽, 黄红卫, 等. 中性粒细胞与淋巴细胞比值联合血清CEA、CA199和CA724检测在早期胃癌筛查中的应用[J]. 实用临床医学, 2022, 23(2): 34-38. DOI: 10.13764/j.cnki.lcsy.2022.02.011.
|
[26] |
Hirahara N, Matsubara T, Kaji S, et al. Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer[J]. Oncotarget, 2023, 14: 71-82. DOI: 10.18632/oncotarget.28353.
pmid: 36719281
|
[27] |
Ishizuka M, Oyama Y, Abe A, et al. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients undergoing surgery for gastric cancer[J]. J Surg Oncol, 2014, 110(8): 935-941. DOI: 10.1002/jso.23753.
pmid: 25146385
|
[28] |
Moschetta M, Uccello M, Kasenda B, et al. Dynamics of neutrophils-to-lymphocyte ratio predict outcomes of PD-1/PD-L1 blockade[J]. Biomed Res Int, 2017, 2017: 1506824. DOI: 10.1155/2017/1506824.
|
[29] |
Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab[J]. J Clin Lab Anal, 2019, 33(8): e22964. DOI: 10.1002/jcla.22964.
|